Veracyte (VCYT) Surges 10.8%: Is This an Indication of Further Gains?Zacks Investment Research • 09/25/26
Veracyte, Inc. (VCYT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/15/26
Veracyte Acquires Convergent Genomics, Expanding its Urology Diagnostics Portfolio with a Urinary Tumor DNA Testing PlatformGlobeNewsWire • 09/14/26
3 Medical Instruments Stocks Banking on GenAI to Tackle Industry WoesZacks Investment Research • 09/09/26
Veracyte to Participate in the Morgan Stanley 24th Annual Global Healthcare ConferenceGlobeNewsWire • 09/01/26
VCYT Drops 25.3% in the Past Month. Is the Sell-Off an Opportunity?Zacks Investment Research • 08/25/26
Down 30.2% in 4 Weeks, Here's Why Veracyte (VCYT) Looks Ripe for a TurnaroundZacks Investment Research • 08/17/26
Earnings Preview: Veracyte (VCYT) Q2 Earnings Expected to DeclineZacks Investment Research • 07/23/26
This Veracyte Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For WednesdayBenzinga • 07/15/26
All You Need to Know About Veracyte (VCYT) Rating Upgrade to Strong BuyZacks Investment Research • 07/08/26
A Veracyte Insider Sold 24,000 Company Shares for $1.1 Million. Here's a Deeper Look at the Transaction.The Motley Fool • 07/04/26
What to Know About This $197,000 Veracyte Insider Sale After a 120% Stock RallyThe Motley Fool • 06/27/26
This Top Biotech Has Surged. CEO Explains Key To Veracyte's Success.Investors Business Daily • 06/16/26